Pemtumomab
Appearance
Monoclonal antibody | |
---|---|
Type | ? |
Source | Mouse |
Target | MUC1 |
Clinical data | |
Trade names | Theragyn |
Routes of administration | Intraperitoneal |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
![]() ![]() |
Pemtumomab (trade name Theragyn) is a mouse monoclonal antibody used to treat cancer. The substance has affinity to various types of cancer, like ovarian cancer and peritoneal cancer, via the polymorphic epithelial mucin (PEM or MUC-1) and delivers the radioisotope Yttrium-90 into the tumour.[1] As of 2009[update], it is undergoing Phase III clinical trials.[2]
It has been granted orphan drug status in Europe.[3]
References
[edit]- ^ Oei AL, Moreno M, Verheijen RH, Sweep FC, Thomas CM, Massuger LF, von Mensdorff-Pouilly S (October 2008). "Induction of IgG antibodies to MUC1 and survival in patients with epithelial ovarian cancer". International Journal of Cancer. 123 (8): 1848–53. doi:10.1002/ijc.23725. PMID 18661524. S2CID 2287723.
- ^ Clinical trial number NCT00004115 for "Monoclonal Antibody Therapy in Treating Patients With Ovarian Cancer or Primary Peritoneal Cancer in Remission Following Surgery and Chemotherapy" at ClinicalTrials.gov
- ^ Antisoma's Lead Product, Pemtumomab Granted European Orphan Drug Status[dead link]
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.